Analysts expect ENDRA Life Sciences Inc. to report revenue of 0.00 for Q2 26, against a range of 0.00 to 0.00. The most recent reported quarter, Q1 26, came in at 0.00.
| Metric | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | - | - | |||
| High Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 18,966.86 | 27,555.19 | 33,497.45 | 13,177.05 | |||
| Low Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 17,390.30 | 24,677.09 | 29,690.97 | 12,090.05 | |||
| Consensus Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 18,178.58 | 26,116.14 | 31,594.21 | 12,633.55 |
Analysts expect ENDRA Life Sciences Inc. to report earnings per share of -0.89 for Q2 26, against a range of -0.96 to -0.82. The most recent reported quarter, Q1 26, came in at -1.09, a 15.5% beat against the -1.29 consensus.
| Metric | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -140.00 | -9.54 | -47.06 | -1.86 | -1.71 | -2.10 | -3.26 | -1.09 | - | - | - | - | - | - | - | - | |||
| High Estimate | -110.24 | -57.05 | -4.02 | -3.67 | -1.93 | -1.77 | -1.08 | -1.17 | -0.82 | -0.81 | -0.79 | -0.78 | 14.58 | 23.06 | 8.58 | 10.68 | |||
| Low Estimate | -128.22 | -64.43 | -4.38 | -4.35 | -2.33 | -1.89 | -1.22 | -1.41 | -0.96 | -0.99 | -0.95 | -0.90 | 12.14 | 21.34 | 7.62 | 9.60 | |||
| Consensus Estimate | -119.23 | -60.74 | -4.20 | -4.01 | -2.13 | -1.83 | -1.15 | -1.29 | -0.89 | -0.90 | -0.87 | -0.84 | 13.36 | 22.20 | 8.10 | 10.14 |